Respiratory seasonal surge expected in Tier 1 metro centers during Aug–Oct 2026. Tier 2 hospitals showing 18% increase in neonatal admissions. Tier 3 referral dependency growing by 11% — consider capacity expansion in high-referral zones. ICU demand forecast exceeds current capacity threshold at Hyderabad and Bengaluru by Sep-2026.

Insurance authorization delays across Tier 1 hospitals extending average discharge cycle by 7.4 hours. PMJAY/Ayushman cases show highest auth delay risk. Dedicating a 4-person authorization desk per Tier 1 hospital can recover ₹1.2–1.4 Cr/month. Unbilled procedure detection through clinical audit can recover additional ₹0.9 Cr/month.

Meropenem and Human Albumin price volatility projected to increase due to imported API dependency. Salbutamol demand forecasted to spike 35% due to seasonal respiratory surge in Aug–Sep. Secure multi-supplier contracts for these 3 drugs immediately. Combined EBITDA exposure: ₹3.6 Cr.

Tier 1 NICU staffing showing elevated overtime risk — 3 hospitals exceeding 180 OT hours/month per unit. Night-shift nursing utilization exceeds threshold in 4 hospitals (Hyderabad, Bengaluru, Chennai, Delhi NCR). Agency cost of ₹0.9 Cr/month can be reduced by 40% through predictive roster optimisation. Attrition risk of 12% requires structured retention programme.

NICU occupancy at 88% across the network — Hyderabad and Bengaluru NICU units projected to hit 96% capacity by Jun-2026. ICU turnaround delay of 6.2 hours is creating downstream bed crunch. OT delay of 41 minutes is reducing effective OT utilization. Combined revenue impact: ₹2.4 Cr/month in lost capacity.

Doctor referral network (42% share) remains the highest-quality lead source with lowest acquisition cost (₹480/patient). Digital channels growing but cost at ₹1,480/patient requires optimisation. Specialty-specific campaigns for NICU and paediatric cardiac surgery can drive 8–10% occupancy uplift in Tier 2 hospitals. Tier 3 referral growth of 11% needs structured hub-and-spoke incentive programme.

Discharge process is the weakest CX touchpoint (81%) — primarily driven by billing wait times and insurance authorization delays adding 7.4 hours to average discharge. OPD wait time of 32 minutes exceeds target of 20 minutes in Tier 1 hospitals. Predictive appointment scheduling can reduce wait time to under 18 minutes and improve NPS by 8–12 points.

₹1.8 Cr annual energy savings recoverable through: HVAC scheduling optimisation in low-occupancy wards (₹0.6 Cr) · Solar panel expansion from 12% to 28% coverage (₹0.5 Cr) · Peak demand load shifting to off-peak tariff windows (₹0.4 Cr) · DG diesel reduction through UPS upgrade (₹0.3 Cr). HVAC alone accounts for 41% of energy cost — highest impact intervention.

ICU transfer congestion between Emergency and PICU during evening hours (18:00–21:00) increasing patient movement delay risk by 24%. Pharmacy-to-ward medication cart routes intersecting with ICU transfer corridors in 3 Tier 1 hospitals. Bio-medical waste segregation compliance at 91% — needs improvement in 4 Tier 2 locations before next inspection.

Hyderabad new tower has highest IRR (26%) due to existing brand strength and NICU demand overflow. Pune expansion delivers fastest ramp-up at 68% occupancy in Year 1 — recommend accelerating timeline. Indore and Bhubaneswar greenfield projects should integrate hub-and-spoke referral model from day 1 to accelerate occupancy. Total incremental revenue potential at full occupancy: ₹180 Cr.

AR days at 48 vs target of 32 represents ₹22–28 Cr of trapped working capital. Reducing AR days to 36 can free ₹16 Cr cash immediately. Procurement centralisation across 30 hospitals can deliver ₹8.4 Cr annual savings. Insurance mix optimisation (reducing PMJAY share from 31% to 24%) can improve cash collection by 18 days.

PerformIQ helps R Children's Hospital leadership predict patient demand, optimise resources, reduce revenue leakage, improve clinical operations, control consumables, strengthen quality compliance, and protect EBITDA before operational inefficiencies impact care delivery. Total addressable EBITDA protection: ₹28–36 Cr annually.